Rentschler Biopharma plans to open new manufacturing site that will be an extension to the existing site in Milford, MA site.
The new state-of-the-art facility includes four new 2,000 L single-use bioreactors and also adds cleanroom space for manufacturing consisting of 22,000 square feet.
The addition of new production site to the existing site is made to further increase the clinical and commercial supply of biopharmaceuticals and expand cGMP manufacturing capacity.
The new facility will be equipped with highly automated production lines consisting of industry 4.0 solutions. Moreover, the site will be designed with advanced technologies, innovative digital and analytical services.
With the increasing manufacturing footprint, the facility will expand its quality control (QC), development, and warehousing capabilities. The new production site doubles the commercial cGMP manufacturing capacity. It is expected that the new site will start its operations in late 2023.